These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7587538)

  • 1. [Crohn disease: prevention and drug therapy].
    Gross V; Andus T; Schölmerich J
    Chirurg; 1995 Aug; 66(8):757-63. PubMed ID: 7587538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group.
    Gross V; Andus T; Fischbach W; Weber A; Gierend M; Hartmann F; Schölmerich J
    Z Gastroenterol; 1995 Oct; 33(10):581-4. PubMed ID: 7502549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
    Feagan BG; Sandborn WJ
    Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The case against routine post-operative therapy for prevention of recurrence in Crohn's disease.
    Breslin NP; Sutherland LR
    Ital J Gastroenterol Hepatol; 1998 Apr; 30(2):226-30. PubMed ID: 9675664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug treatment of Crohn's disease].
    van Deventer SJ; Tytgat GN
    Ned Tijdschr Geneeskd; 1998 May; 142(21):1191-5. PubMed ID: 9627451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug treatment of chronic inflammatory bowel diseases: current status and prospects].
    Seibold F; Wagner AC; Göke B
    Schweiz Med Wochenschr; 2000 Feb; 130(7):222-32. PubMed ID: 10719713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budesonide in glucocorticoid dependent chronic active Crohn's disease; a pilot study.
    Novacek G; Kleinberger M; Vogelsang H; Moser G; Lochs H
    Z Gastroenterol; 1995 May; 33(5):251-4. PubMed ID: 7610692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of active Crohn's ileocolitis with oral pH-modified budesonide. Germany Budesonide Study Group.
    Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
    Z Gastroenterol; 1995 May; 33(5):247-50. PubMed ID: 7610691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: chronic active disease and maintaining remission in Crohn's disease.
    Kamm MA
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():102-5. PubMed ID: 15352904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Local or systemic treatment of inflammatory bowel diseases?].
    Schmassmann A; Halter F
    Ther Umsch; 1993 Feb; 50(2):94-9. PubMed ID: 8096092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current treatment for prevention of relapse and recurrence in Crohn's disease.
    Prantera C; Scribano ML
    Ital J Gastroenterol Hepatol; 1999; 31(6):515-8. PubMed ID: 10575572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapy of chronic inflammatory bowel diseases].
    Beglinger C
    Ther Umsch; 1997 Nov; 54(11):649-53. PubMed ID: 9454368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance of surgically induced remission of Crohn's disease.
    Froehlich F; Juillerat P; Pittet V; Felley C; Mottet C; Vader JP; Michetti P; Gonvers JJ
    Digestion; 2007; 76(2):130-5. PubMed ID: 18239404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical treatment of inflammatory bowel disease: new therapies, new drugs.
    Sutherland LR
    CMAJ; 1987 Nov; 137(9):799-802. PubMed ID: 2894889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Postoperative recurrence in Crohn's disease].
    Caprilli R; Taddei G; Viscido A
    Chir Ital; 1995; 47(5):25-32. PubMed ID: 9162601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Azathioprine and 5-ASA in the prevention of postoperative recurrence of Crohn's disease].
    Nos P; Hinojosa J; Aguilera V; Molés JR; Pastor M; Ponce J; Berenguer J
    Gastroenterol Hepatol; 2000 Oct; 23(8):374-8. PubMed ID: 11227650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease.
    Kim PS; Zlatanic J; Korelitz BI; Gleim GW
    Am J Gastroenterol; 1999 Nov; 94(11):3254-7. PubMed ID: 10566725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical management of patients with difficult-to-treat inflammatory bowel disease.
    van Hogezand RA
    Neth J Med; 1994 Aug; 45(2):55-9. PubMed ID: 7936006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.
    Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
    Hepatogastroenterology; 1997; 44(14):445-51. PubMed ID: 9164517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
    Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
    Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.